BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
April 1, 1999
View Archived Issues
Aurora and Becton Dickinson announce drug development agreement
Read More
Procept receives additional patent allowances for PRO-2000
Read More
MGI Pharma to promote Ridaura and Luxiq for Connetics
Read More
DSMB completes interim evaluation of Maxamine phase III clinical trials
Read More
SciClone receives another approval for Zadaxin
Read More
Inflazyme lays plans for phase I testing of IPL-576092
Read More
Aquila initiates phase IIb testing of Quilimmune-P
Read More
New microbially produced inhibitor of HSP expression in development at Mercian
Read More
Temporary platelet inhibition by SM-20302 results in sustained antithrombotic efficacy in dog model
Read More
Xenova: year-end 1998 highlights
Read More
New microtubule-stabilizing agents developed at Schering
Read More
Dopaminergic agents for anxiety, depression and Parkinson's disease disclosed by ADIR
Read More
Merck & Co. presents new macrolide immunosuppressants
Read More
Protein farnesyltransferase inhibitors emerge from Schering-Plough/Pharmacopeia collaboration
Read More
More from ACS meeting: Pfizer presents potent new leukotriene antagonists with oral activity
Read More
New antimuscarinic piperidine derivative from Taisho inhibits bladder contractions
Read More
Dihydropyridines for reversing MDR presented at Japanese scientific meeting this week
Read More
Selective N-type VACC blockers under investigation at Warner-Lambert and Elan
Read More
First regulatory approval sought for Reminyl for Alzheimer's disease
Read More
Aronex regains worldwide marketing rights to Atragen
Read More